Banyan Biomarkers, Inc. Works with Emory University to Analyze Biomarkers in the Clinical Trial of Progesterone in Traumatic Brain Injury
Banyan Biomarkers, Inc. will partner with Emory University through a
grant from the National Institutes of Health to measure biomarkers in
the blood of traumatic brain injury (TBI) patients. The five-year grant
of $2.2 million was awarded to Michael Frankel, MD, Professor of
Neurology at Emory School of Medicine, with partners Banyan Biomarkers,
Inc., the Medical University of South Carolina, the University of
Pittsburgh and the University of Michigan. The research team will study
biomarkers in the blood of TBI patients enrolled in the phase III
clinical trial, ProTECT III (Progesterone for Traumatic Brain Injury,
Experimental Clinical Treatment), which is assessing the efficacy of
progesterone in the treatment of TBI.
Read more... ..